Henlius Receives NMPA Approval for its First Innovative Monoclonal Antibody HANSIZHUANG

/PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that its first self-developed innovative PD-1 inhibitor HANSIZHUANG (generic name:...

Related Keywords

China ,Georgia ,United States ,Tongji ,Sichuan ,Shanghai ,Poland ,Turkey ,Chinese ,Kalbe Genexine Biologics ,Li Jin ,Zhang Wenjie ,Qin Shukui ,Wray Mcdermott ,Prnewswire Shanghai Henlius Biotech Inc ,Tongji University ,Tumor Center ,European Union ,National Medical Products Administration ,Department Of Oncology ,Chinese Society Of Clinical Oncology ,Henlius Biotech ,Microsatellite Instability High ,Executive Director ,Nanjing Jinling Hospital ,Shanghai East Hospital ,Chinese Society ,Clinical Oncology ,Genexine Biologics ,Patients With ,Mismatch Repair Deficient Cancer ,Results From ,Henlius ,